Bcl-2 family proteins are essential for platelet survival
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Platelets are relatively short-lived, anucleated cells that are essential for proper hemostasis. The regulation of platelet survival in the circulation remains poorly understood. The process of platelet activation and senescence in vivo is associated with processes similar to those observed during apoptosis in nucleated cells, including loss of mitochondrial membrane potential, caspase activation, phosphatidylserine (PS) externalization, and cell shrinkage. ABT-737, a potent antagonist of Bcl-2, Bcl-X(L), and Bcl-w, induces apoptosis in nucleated cells dependent on these proteins for survival. In vivo, ABT-737 induces a reduction of circulating platelets that is maintained during drug therapy, followed by recovery to normal levels within several days after treatment cessation. Whole body scintography utilizing ([111])Indium-labeled platelets in dogs shows that ABT-737-induced platelet clearance is primarily mediated by the liver. In vitro, ABT-737 treatment leads to activation of key apoptotic processes including cytochrome c release, caspase-3 activation, and PS externalization in isolated platelets. Despite these changes, ABT-737 is ineffective in promoting platelet activation as measured by granule release markers and platelet aggregation. Taken together, these data suggest that ABT-737 induces an apoptosis-like response in platelets that is distinct from platelet activation and results in enhanced clearance in vivo by the reticuloendothelial system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, targeting BCL-XL with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [6]
In the citing paper
“a potential clinical limitation of BCL-XLi is the fact that these inhibitors can cause on-target, reversible thrombocytopenia (Zhang et al., 2007).”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Zhang et al., 2007
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a small molecule antagonist of the prosurvival Bcl-2 family proteins Bcl-XL, Bcl-2, and Bcl-w that induces apoptosis in tumor cells in a mitochondria-dependent fashion.(18) Treatment of ABT-737 in dogs leads to a rapid, dosedependent decrease in circulating platelets that return to baseline within 72-h post…”
BackgroundSelf-citationA receptor for phosphatidylserine-specific clearance of apoptotic cells
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A. B., & Henson, P. M. (2000) · Nature · doi:10.1038/35011084 · Cited by 1,491 · cited 1×
“PS externalization on cells has also been shown to signal the specific engulfment of these unwanted cells by phagocytes leading to clearance from the circulation .(9,15,25) Finally, the fact that the enantiomer negative control does not activate the apoptotic cascade at equivalent concentrations supports the notion th…”
BackgroundThe biogenesis of platelets from megakaryocyte proplatelets
Patel, S. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26891 · Cited by 603 · cited 1×
“The similarities between platelet biogenesis from megakaryocytes and apoptosis include membrane blebbing, membrane condensation, DNA fragmentation, cell shrinkage, and ultimately the formation of apoptotic bodies.(5,6) The consequence of this apoptotic process is that each mature megakaryocyte fragments into thousands…”
BackgroundThe platelet release reaction: granules' constituents, secretion and functions
Rendu, F., & Brohard-Bohn, B. (2001) · Platelets · doi:10.1080/09537100120068170 · Cited by 599 · cited 4×
“Upon platelet activation, a series of granules are released that are essential for the full activation response.(21) To further investigate other direct effects of ABT-737 on platelet dynamics, isolated platelets were treated with ABT-737 and classical markers of granule release were monitored.”
BackgroundMethodInfluentialProgrammed cell death and Bcl-2 protection in the absence of a nucleus.
Jacobson, M. D., Burne, J. F., & Raff, M. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06459.x · Cited by 552 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundMartin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., & Green, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28753 · Cited by 372 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundWolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes, G. P., Salvesen, G. S., & Green, D. R. (1999) · Blood · doi:10.1182/blood.v94.5.1683 · Cited by 323
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242 · cited 1×
“The process of apoptosis can be viewed as a cascade of events initiating from the accumulation of a death signal(s), release of apoptotic factors from the mitochondria, activation of initiator/effector caspases, ultimately leading to cell death.(16) Our studies demonstrate that ABT-737 initiates the apoptotic cascade…”
BackgroundA Simple Nonradioisotope Technic for the Determination of Platelet Life-Span
Stuart, M. J., Murphy, S., & Oski, F. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197506192922502 · Cited by 242 · cited 1×
“released into the circulation, platelets rapidly age with a halflife of 4–5 days.(7,8) As platelets age, they lose their ability to function and are subsequently removed from circulation.”
BackgroundRole of platelets in thrombosis and hemostasis
Packham, M. A. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-043 · Cited by 215 · cited 2×
“Subsequent platelet activation, granule release, and aggregation are essential for the formation of a hemostatic plug that limits blood loss and stimulates repair.(2) There are several morphological changes associated with platelet activation that are reminiscent of nucleated cell apoptosis.”
Background
Cited by
Items 401–452 of 452
Keuling, A. M. (2010) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3cq5d
Liu, Q., Atkinson, J. M., Gebru, M. T., Clements, K. E., Moldovan, G., & Wang, H. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/665505
“[5,6] Highly potent Bcl-xL inhibitors have also been developed, but 39 clinical use is limited due to dose-limiting thrombocytopenia [7,8].”
Reed, J. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm013
Role of the Bcl-2 family of cell death regulators at the Endoplasmic Reticulum
Jabbour, L. (2020) · theses.fr (ABES) · doi:10.70675/5c461851zfd1bz4f8ez814fz8469a2b26a04 · Cited by 3
Phospholipid Flippases in B cells and Platelets
Jing, W. (2019) · ANU Open Research (Australian National University) · doi:10.25911/5f58b08d6e40d
Gandhi, V. V., & Bose, P. (2017) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.725314829.793538197
Faculty Opinions recommendation of Fisetin is a senotherapeutic that extends health and lifespan.
Schumacher, B. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734139615.793563345
Research Progress of Venetoclax for the Treatment of Multiple Myeloma
夏, 静. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.127911
Reed, J. C. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm013.pub2
Data from ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P. M., et al. (2023) · doi:10.1158/0008-5472.c.6498161
Self-citationBalachander, S. B., Criscione, S. W., Byth, K. F., Cidado, J. R., Adam, A., Lewis, P. M., Macintyre, T., Wen, S., Lawson, D., Burke, K. A., et al. (2023) · doi:10.1158/1078-0432.c.6529392.v1
Balachander, S. B., Criscione, S. W., Byth, K. F., Cidado, J. R., Adam, A., Lewis, P. M., Macintyre, T., Wen, S., Lawson, D., Burke, K. A., et al. (2023) · doi:10.1158/1078-0432.c.6529392
Wang, Z., Gomchok, D., Ye, Y., Wen, Y., & Wuren, T. (2025) · Hämostaseologie · doi:10.1055/a-2462-6667
“43 We speculated that the decrease in platelet count under hypoxia might be related to apoptosis, and subsequently veri fi ed whether platelet apoptosis was increased under hypoxia.”
Особенности исследования функций тромбоцитов в условиях микрогравитации
Сергеева, Е. А. (2025) · Nauchno-prakticheskii zhurnal «Patogenez» · doi:10.48612/path/2310-0435.2025.01.17-24
Zoeller, J. J., Vagodny, A., Daniëls, V. W., Taneja, K., Tan, B. Y., DeRose, Y. S., Fujita, M., Welm, A. L., Letai, A. G., Leverson, J. D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433107
Zoeller, J. J., Vagodny, A., Daniëls, V. W., Taneja, K., Tan, B. Y., DeRose, Y. S., Fujita, M., Welm, A. L., Letai, A. G., Leverson, J. D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14433110
Khan, S., Wiegand, J. S., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19327084
In vitro effects of cold storage on human and 13-lined ground squirrel platelet apoptosis
Splinter, N. P. (2021) · Minds at UW (University of Wisconsin)
Recent advance in the targeted protein degradation technology for overcoming acute leukemia
Jin, X., Shi, Z., Liang, Z., Chen, J., Wang, C., Lou, Y., Cao, X., Zhu, L., Zhao, Y., Zhao, C., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100331
Self-citationBcl-xL blockade targets neutrophils and synergizes with chemotherapy in lung squamous cell carcinoma
Mayet, A., Parma, B., Lécuyer, D., Defruit, A., Rana, S., Bodac, A., Demetter, P., Denanglaire, S., Ireland, A. S., Brandão, M., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00401-z
“Indeed, dual Bcl-2/Bcl-xL inhibitors (ABT-737 or navitoclax) induce thrombocytopenia, as platelet survival depends on Bcl-xL (Mason et al, 2007; Zhang et al, 2007).”
Crossroad between metabolism and immunity in cancer treatment
Zunino, B. (2014) · theses.fr (ABES) · doi:10.70675/4c08e224z28e0z485eza09cz14b8900b8a06
The Role of DIAPH1 in the Megakaryopoiesis
Pan, J. (2014) · theses.fr (ABES) · doi:10.70675/3d0829d2zfc18z4bc0z8e26ze0030ccb042f
Anti-plaquettaires et risque hémorragique : rôle du CD40L
Grosdidier, C. (2014) · theses.fr (ABES) · doi:10.70675/d2361bc1zbad2z4fafz8d2cze117614aca75
Caractérisation et études précliniques d'un nouvel inhibiteur naturel de MCL-1
Daressy, F. (2020) · theses.fr (ABES) · doi:10.70675/4e4153f4zba2dz49bcz9862z38251f3f7882
Bcl2L10 : polymorphisme, résistance oncogénique et conséquences thérapeutique dans le cancer du sein
Quang, D. M. (2021) · theses.fr (ABES) · doi:10.70675/86dd7fafzcb40z4cedz8eb7zbb41268cd809
Mohiuddin, M. (2026) · Health Science Reports · doi:10.1002/hsr2.72506 · Cited by 1
Podoplelova, N. A., Obydennyi, S. I., Ignatova, A. A., Soloveva, P. A., Chabin, I. A., Dasgupta, A. K. G., Андреевна, Ф. А., Starostin, N. N., Sokolov, A. V., Kireev, I. I., et al. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109764
Lee, Y., Kwon, E., Gajulapalli, S. R., Paik, J. Y., Orlikova-Boyer, B., Silva, A. M. S., Cha, H., Cerella, C., & Diederich, M. F. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-09000-9
“Across all cohorts, only bone marrow-derived samples collected at initial diagnosis were used to minimize biological heterogeneity and ensure comparability among datasets.”
Robinson, Z. R., Fong, S. C., Choi, D. Y., Siopack, S., Bolanos-Campos, A., Morshedian, N., Utke, E., Kanda, M., Kato, C., Conboy, M. J., et al. (2026) · Aging · doi:10.18632/aging.206399
“Platelets rely on BCL-XL for survival [45] and while reducing the dose of ABT-263 can minimize its toxicity, this also reduces anti-cancer efficacy.”
Wang, C., Wu, C., Wang, G., Wang, K., 费世江, Zong, Y., Dong, X., Zhang, S., & Zhou, R. (2026) · Medicine · doi:10.1097/md.0000000000051010
“[6,7] Standard treatments for thrombocytopenia include platelet transfusions, corticosteroid therapy, and intravenous immunoglobulin.”
BindingDB (2022) · UC San Diego · doi:10.7270/q2r2155t
BindingDB (2022) · UC San Diego · doi:10.7270/q2542s8d
BindingDB Entry 50012486: Structure-Based Design of A-1293102, a Potent and Selective BCL-X
BindingDB (2022) · UC San Diego · doi:10.7270/q2r78jw5
BindingDB Entry 50009085: The chemical biology of apoptosis: Revisited after 17 years.
BindingDB (2021) · UC San Diego · doi:10.7270/q2r78jmk
BindingDB (2014) · UC San Diego · doi:10.7270/q2x92cqt
BindingDB Entry 50032446: Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR.
BindingDB (2011) · UC San Diego · doi:10.7270/q2j103c3
BindingDB Entry 6111: Structure-guided design of a selective BCL-X(L) inhibitor.
BindingDB (2014) · UC San Diego · doi:10.7270/q2qj7fz7
BindingDB Entry 50044566: Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.
BindingDB (2015) · UC San Diego · doi:10.7270/q2kp83qg
BindingDB Entry 50015437: Discovery of a Novel BCL-X
BindingDB (2023) · UC San Diego · doi:10.7270/q2nk3jx7
BindingDB (2016) · UC San Diego · doi:10.7270/q2vx0j43
Targeting Apoptotic Pathways in Melanoma
Hersey, P., & Zhang, X. D. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_9
Metadata
- Authors
- Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., Preusser, L. C., Reinhart, G. A., Smith, M. L., Rosenberg, S. H., Elmore, S. W., & Tse, C.
- Affiliations
- Abbott (United States) (US)
- Corresponding author
- Elmore, S W
- Tse, C
- Venue
- Cell Death & Differentiation
- Published
- 2007-01-05
- Volume
- 14
- Issue
- 5
- Pages
- 943-951
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1976197588
- Cited by
- 427
- References
- 32
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 20 · 2022: 28 · 2021: 38 · 2020: 31 · 2019: 15 · 2018: 24 · 2017: 27 · 2016: 27 · 2015: 23 · 2014: 27 · 2013: 26 · 2012: 21
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- platelet survival, Bcl-2 family proteins, ABT-737, platelet clearance, caspase-3 activation, cytochrome c release, phosphatidylserine exposure, mitochondrial membrane potential, reticuloendothelial system, hepatic clearance, platelet activation, hemostasis
- MeSH terms
- Animals, Biphenyl Compounds, Blood Platelets, Cell Separation, Cell Survival, Cytoplasmic Granules, Dogs, Dose-Response Relationship, Drug, Exocytosis, Flow Cytometry, Humans, Liver, Male, Nitrophenols, Phosphatidylserines, Piperazines, Platelet Aggregation, Platelet Count, Sulfonamides, Apoptosis, Proto-Oncogene Proteins c-bcl-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.